Integrating Analytical Procedures in Routine Practices of Centralized Antiblastic Compounding Units for Valorization of Residual Compounded Drugs
- PMID: 39861749
- PMCID: PMC11769000
- DOI: 10.3390/pharmaceutics17010101
Integrating Analytical Procedures in Routine Practices of Centralized Antiblastic Compounding Units for Valorization of Residual Compounded Drugs
Abstract
Background/objectives: Although extemporaneous formulations of anticancer drug products for personalized therapy are produced according to Good Hospital Pharmacy Manufacturing Practice, the lack of knowledge about drug stability under clinical conditions limits the second-time use of these highly costly medications in clinical practice. Therefore, the residual compounded drugs are considered waste and a cost item that negatively affects the healthcare system. In the context of the ever-increasing interest of the health system in applying practices in line with personalized medicine and spending review policies, this research aimed to demonstrate the feasibility of incorporating analytical techniques into daily routine practice. Specifically, the present research focused on fast stability analysis of Active Pharmaceutical Ingredients (APIs) in antiblastic residual compounded drugs with the purpose of demonstrating their potentialities as a resource for possible second-time use.
Methods: Two different subsets of drug products were analyzed, i.e., medicines containing small molecules and medicines containing monoclonal antibodies. In relation to their different physicochemical properties, two analytical approaches were optimized and involved in the stability investigation: HPLC-DAD for small molecules and a combined approach of LC-MS/MS with size exclusion chromatography for monoclonal antibodies analysis.
Results: Results underlined that the stability data, as available in the summary of product characteristics related to each medicine, do not completely describe the physicochemical shelf-life of anticancer compounded drugs.
Conclusions: In fact, for all tested products, our results suggested a longer shelf-life in comparison to the datasheet, giving hospital pharmacists the possibility to extend the clinical use of compounded drugs, improving the cost-benefit of anticancer personalized therapy.
Keywords: anticancer medicines; hospital compounded drugs; personalized medicine; physicochemical stability investigation.
Conflict of interest statement
The authors declare no conflicts of interest.
Figures
Similar articles
-
Prevalence, determinants, and characteristics of extemporaneous compounding in Jordanian pharmacies.BMC Health Serv Res. 2019 Nov 8;19(1):816. doi: 10.1186/s12913-019-4684-y. BMC Health Serv Res. 2019. PMID: 31703672 Free PMC article.
-
Potential risks of pharmacy compounding.Drugs R D. 2013 Mar;13(1):1-8. doi: 10.1007/s40268-013-0005-9. Drugs R D. 2013. PMID: 23526368 Free PMC article. Review.
-
Patient safety issues associated with the use of compounded medicines as alternatives to approved pharmaceutical products in Europe and how best practice can improve outcomes.Int J Risk Saf Med. 2020;31(3):133-144. doi: 10.3233/JRS-200002. Int J Risk Saf Med. 2020. PMID: 32538874 Review.
-
Pharmaceutical compounding of orphan active ingredients in Belgium: how community and hospital pharmacists can address the needs of patients with rare diseases.Orphanet J Rare Dis. 2019 Aug 1;14(1):186. doi: 10.1186/s13023-019-1154-x. Orphanet J Rare Dis. 2019. PMID: 31370862 Free PMC article.
-
Extemporaneous compounding in veterinary practice: a New Zealand perspective.N Z Vet J. 2013 Nov;61(6):311-5. doi: 10.1080/00480169.2013.773853. Epub 2013 Apr 2. N Z Vet J. 2013. PMID: 23544952
References
-
- Khashayar V., Jason R., Linda S.F., Samir F. Optimizing physician staffing and resource allocation: Sine-wave variation in hourly trauma admission. J. Trauma. 2007;62:610–614. - PubMed
Grants and funding
LinkOut - more resources
Full Text Sources